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Abstract
The mammalian kidney is a complex organ, requiring the concerted function of up to millions
of nephrons. The number of nephrons is constant after nephrogenesis during development,
and nephron loss over a life span can lead to susceptibility to acute or chronic kidney disease.
New technologies are under development to count individual nephrons in the kidney in vivo.
This review outlines these technologies and highlights their relevance to studies of human renal
development and disease.
Introduction
The mammalian kidney is a complex organ that has evolved to control a wide range of
physiological processes. These processes include blood volume, blood pressure, osmotic
pressure, waste removal, and metabolite homeostasis. Normal kidney development requires
reciprocal formation of the ureteric bud and metanephric mesenchyme. This is followed
by an iterative branching process and cascade of signaling to maintain a renewable pool of
progenitor cells, which produce the differentiated cells that perform the diverse functions of
the kidney.1,2
The duration and end of nephrogenesis vary across species. In humans and nonhuman
primates, birth and the end of human nephrogenesis occur at similar time points; nephrogenesis
ends at about 35 weeks of gestation humans.3 Species that deliver litters of offspring often have a
variable period of natural postnatal nephrogenesis.4 Nephron number varies by species, strain,
sex, and environmental and genetic factors.5 Human nephron number is highly variable
(200,000–2.7 million), based on studies at autopsy.6–10 A wide range of nephron numbers
has also been observed in human neonatal autopsy, suggesting this range is established during
nephrogenesis.11
Nephron number may determine susceptibility to numerous renal pathologies,12–14 and
nephron loss can accelerate the development of chronic kidney disease (CKD).15 It is thus
important to consider the causes of low nephron number and loss and to understand why such
a wide range in nephron number remains in humans. There is increasing evidence that genetics
and epigenetic factors determined by maternal health and nutrition are critical determinants of
nephrogenesis. Fetal development is constrained by energy available from the mother, regulated
by placental function. Evolutionary selection pressure governed by reproductive fitness has
prioritized brain growth over fetal and early postnatal kidney development,16 with over 50%
of resting metabolic rate being allocated to the brain through the first year of life. Thus, maternal
undernutrition, environmental stress, or infection lead to intrauterine growth restriction or
premature delivery and downregulation of DNA methylation in nephron progenitor cells.
The molecular mechanisms necessary to develop a healthy kidney have been mainly studied
in rodent models. However, until recently, there were few direct comparisons between renal
development in rodents and in humans.17,18
Nephron loss is typically overcome through hypertrophy and hyperfiltration of the remain-
ing nephrons, evidenced by maintenance of whole kidney glomerular filtration rate (GFR).
Hypertrophy is a short-term adaptation to maintain metabolic homeostasis through reproduc-
tive years. However, there are physical constraints on adaptive hypertrophy, limited by tubular
surface area necessary for transport and resistance to flow resulting from increasing tubular
length.19 This constraint is overcome in the largest mammals (whales) by packaging 100 million
nephrons into small unipapillary units that contain short tubules.20 Beyond reproductive years,
increasing cellular oxidative injury resulting from accumulating stressors (ischemia, hypoxia,
infection) promotes continued nephron loss that is superimposed on senescence, reflected
by a 50% reduction in nephron number in the normal aging population.21,22
Despite our growing understanding of renal development and the role of the gestational
environment in establishing renal health, we still lack an integrated view of individual
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nephrons in the context of the intact, functioning organ. Current
nonbiased methods for estimating glomerular number require
destruction of the kidney, limiting their potential in longitudinal
analysis and use in vivo. The development of noninvasive imaging
techniques to track the number of functioning nephrons through-
out the life cycle would provide key information to predict the
progression of CKD and to measure the effectiveness of new
interventions.
New radiological tools are being developed to address these
challenges and provide a noninvasive means of tracking and
measuring nephronmass in vivo. This technology has the potential
to provide new insights into renal development and its role in
disease progression later in life. Observations available through
this technology include nephron number, glomerular volume
and hypertrophy, and possibly single-nephron function. This
review will outline the current state of this new technology and
provide a view of its potential applications in preclinical science
and clinical investigations.
Ex vivo approaches to measuring nephron number and
glomerular size
The most extensively developed approaches to measure nephron
number and glomerular size are based ondesign-based stereology.23,24
Tissue is prepared and sectioned for microscopy, and the sizes of
the structures, such as glomeruli, that are observed on the slides
are analyzed to infer average volumes of the structures in the original
tissue. This can be performed in excised organs or from biopsy tissue
by systematically and randomly sampling the tissue. The dissector–
fractionator technique has revealed population-based differences in
nephron number and hyperfiltration in humans25 and has been used
extensively to study animal models of human diseases.
Fig. 1. In vivo 3D cationized ferritin-enhanced MRI40 (CFE–MRI) to detect renal glomeruli. (A and B) Sprague–Dawley rats (n= 8) were imaged on a plastic bed and a custom RF
probe was designed for single kidney imaging. “C” are capacitors in the resonator circuit and “L” are inductors. (C) In vivo MRI of a rat kidney after intravenous (IV) injection of
cationized ferritin (CF) revealed dark punctate labeling in the kidney cortex, consistent with CF labeling on the GBM. A typical image is shown. (d) A custom algorithm identified
CF-labeled glomeruli against tissue background, mapping them in 3D within the whole kidney, marked here using a random color map. (e–g) A control experiment of a rat before
and after CF administration revealed spurious background variations in cortex before CF administration and distinct punctate labeling afterward. (h) Ex vivoMRI of the same kidney
also revealed dark punctate labeling within the rat kidney cortex validating CF labeling onto the GBM. Scale bars: b, both insets= 10mm; c–e= 1mm; c and d, insets= 0.5 mm;
f and g= 0.1 mm; h= 1.5 mm. Reproduced with permission from Baldelmar et al.40
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To avoid the sectioning required by stereology, new imaging
approaches were recently developed to supplement biopsy data
and to measure nephron number. Magnetic resonance imaging
(MRI) is most often based on the detection of water protons in tis-
sue, primarily from water, using magnetic fields. The subject
or sample is placed inside a large magnetic field. Typical magnetic
field strengths used for clinical MRI range from 1.5 to 7T.
Preclinical MRI systems often employ much larger field strengths
for high signal-to-noise and improved image contrast and resolu-
tion. MRI provides a wide range of image contrast techniques to
image soft tissue and does not require ionizing radiation. MRI also
provides high resolution in both preclinical and clinical systems.
Cationized ferritin (CF) was introduced as an intravenously
injected contrast agent to detect and image glomeruli throughout
the kidney by MRI.26 Charged nanoparticles, including ferritin,
had been used for decades to investigate the structure and function
of the basement membrane using electron microscopy (EM). CF
was originally created as a tracer for EM by Danon,27 who showed
that it could bind to anionic sites. The ferritin molecule is detected
in EM because of its electron-dense iron oxide core. This same iron
oxide core is often magnetic, making it detectable by MRI.26,28,29
This technique, CF-enhanced MRI (CFE–MRI), has been used
to count every glomerulus in healthy rat kidneys,30 ex vivo, and
was used to measure the intrarenal distribution of glomerular
volumes. CFE–MRI was also used to count and measure every
glomerulus in the mouse kidney,31 and glomerular volumes were
mapped to reveal spatial variation in glomerular size. These
findings have been confirmed by multiple groups.32,33 Both rat
and mouse measurements using CFE–MRI were validated by
dissector–fractionator stereology.
CFE–MRI has also been performed in intact human donor
kidneys,34 where CF was injected directly into the renal artery
and the kidney was flushed with saline before it was fixed and
imaged. CFE–MRI in human kidneys provided a three-dimensional
view of the renal glomerular morphology, showing heterogeneous
glomerular hypertrophy and regions of nephron loss likely associ-
ated with the patient’s untreated hypertension. Regions of nephron
loss were correlated with histology from the same regions, demon-
strating both vascular and glomerular sclerosis.
These initial studies focused on changes in nephron number and
glomerularmorphology with both chronic and acute kidney disease.
In Bennett et al.,26 the distribution of CF in the kidney was redistrib-
uted due to early glomerular pathology in a rat model of focal and
segmental glomerulosclerosis, before presentation of proteinuria. In
mice, CFE–MRI has been applied to detect and map glomerular
hypertrophy in the oligosyndactylism (Os/þ) model of nephron
reduction.31 More recently, we showed that acute kidney injury in
a neonatal rabbit model caused a detectable loss of glomeruli with
vascular reorganization.35 Thus, tracking changes in CF labeling by
MRI may be an important tool to understand the impact of damage
during development and its impact of renal health later in life.
There are some important considerations in validating CFE–
MRI using other techniques, such as the dissector–fractionator
stereology employed in these early studies. CFE–MRI can only
measure glomeruli that are perfused, while histological approaches
also detect glomeruli that are not. If the two are directly compared
when there are under- or unperfused glomeruli, MRI measure-
ments will be lower. Structural and functional factors, such as
oncotic pressure, capillary perfusion rates, and glomerular base-
ment membrane (GBM) structure, which affect CF accumulation
in the GBM, are poorly understood, so it is possible that glomerular
uptake is modulated by disease processes that modulate the
CFE–MRI in ways that have not been described. Finally, GBM dam-
age or proteinuria may cause leakage of the CF into the tubules,
leading to diffuse rather than punctate labeling of glomeruli
observed byMRI. In studies of development, the GBM charge struc-
ture and glomerular filtration vary with gestational age. In all of
these cases, it is important to understand the parameters involved
in CF labeling through continued investigations. It is also critical
to establish the toxicology of CF, which appears minimal in healthy
animals but must be investigated with each new model.
X-ray–CT has been recently demonstrated for the measure-
ment of renal microstructure36 and mapping nephron number37
in the intact kidney, ex vivo. A primary advantage of CT is its sim-
plicity and speed of use and low cost compared toMRI. A disadvant-
age is the use of ionizing radiation, which can limit its use in vivo
or in clinical applications. Nonetheless, CT offers high-resolution
imaging of labeled structures ex vivo that can then be co-registered
with soft tissue anatomy using other imaging modalities.
Light sheet microscopy after whole-organ optical clearing has
been used to measure glomerular number and capillary tuft size in
intact mouse kidneys.38 This attractive approach has the advantage
of automation and visualization of the entire glomerulus at micro-
scopic resolution in the whole organ or in samples of large organs.
In vivo approaches to directly measure nephron number
and glomerular size
Established and emerging tools to measure nephron number
ex vivo have made it possible to infer the inter and intrasubject
heterogeneity in nephron number and glomerular volume.
These tools are beginning to address critical gaps in our knowledge
of kidney structure and how it relates to function in the kidney,
in vivo. These questions include (1) What is the relationship
between glomerular number and size with individual nephron
filtration? (2) What is the spatial distribution of nephron number
and glomerular size and its relationship to pathology? and (3) Does
the rate of glomerular senescence change in health and kidney
disease? Clinically, it is possible to estimate nephron number
in vivo using a combination of X-ray/CT and biopsy.39 This type
of work is beginning to provide a critical link between nephron
number and renal function. Several publications have demon-
strated that MRI can be used to detect individual glomeruli in a
living animal.26,40–43 The early work in this area using CFE–MRI
was limited to specific regions of the kidney. In one report, a
wireless amplifier was developed to locally increase signal in the
kidney to allow for co-registration of single nephrons during
filtration and function.42 More recently, two publications have
reportedmeasurements of individual glomeruli in vivo in the entire
kidney by CFE–MRI in both rats and inmice.40,41 In vivo CFE-MRI
in the rat is shown in Figure 1. This approach was also used in a
longitudinal experiment, demonstrating that CFE–MRI can poten-
tially be used to monitor changes in nephron number over time in
response to therapy or to track renal development.
A primary challenge with CFE–MRI in vivo is sensitivity.
Deoxyhemoglobin in the blood is paramagnetic and can cause a
magnetic susceptibility artifact in the capillaries that reduces the
dynamic range for detecting glomeruli labeled with CF. To address
this, ferritin can be modified to incorporate more iron,29,44–46 and
the metal oxide core of the CF can be modified to make it more
readily detectable without the susceptibility artifact.43 However,
other detection strategies come with trade-offs in product yield
or imaging speed, so the first demonstration of CFE–MRI did
not use these approaches. The key to CFE–MRI is to control
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motion and to ensure that the radiofrequency (RF) coil is suffi-
ciently sensitive over the entire kidney.
Outlook for developmental nephrology: structure and
function
Here, we have described emerging tools to directly measure
nephron endowment, both ex vivo and in vivo. X-ray–CT provides
rapid image acquisition and phenotyping, ex vivo. Tools such as
X-ray–CT combined with biopsy have the advantage of being
rapidly deployed in the clinic, with a disadvantage of invasiveness,
use of ionizing radiation, and potential for sample bias. MRI-based
approaches overcome the need for ionizing radiation and provide
combined soft tissue contrast and can be used both ex vivo and
in vivo. CFE–MRI requires injection of a contrast agent whichmust
be deemed safe before it can be used in the clinic. While in vivo
measurement of nephron number is in its infancy, new image
acquisition sequences for rapid imaging, in addition to improved
hardware and image processing, have the potential to make these
MRI tools practical for routine use. As the technique matures,
other pulse sequences will be deployed to reduce sensitivity to
the CF-induced susceptibility artifact, and the physics of the local
magnetic environment will be better understood to potentially
reveal even more information. There are also unique opportunities
to combine glomerular and tubular morphology with other image
acquisition strategies to provide a complete view ofmicrostructure,
gross anatomy, and physiology in the kidney in vivo. This
combined information can be used to study the development of
nephron loss over time, a primary feature of both acute and
CKDs and progressive kidney diseases during development.
The recent refinement of image visualization and segmentation,
through analytical tools or by artificial intelligence, makes it
possible to extract large amounts of information from three-
dimensional images of tissue. Some emerging techniques, such
as susceptibility tensor imaging,47,48 promise to provide new infor-
mation that can be used as a surrogate for tissue microstructure. In
the kidney, this can facilitate combinedmaps of glomeruli, tubules,
vasculature, and interstitium from a combination of co-registered
images. It may also be possible to directly co-register these images
to optical imaging or to information obtained by other radiological
imaging modalities. It is important in each case to extensively
validate these new tools and to eventually standardize some
acquisition protocols across institutions to provide a high level
of reproducibility. The availability and ease of use of new tools will
likely drive new approaches in data science to integrate informa-
tion from all of these contrast mechanisms andmodalities to offer a
new, quantitative view of the kidney in large numbers of subjects.
In development, these tools may be eventually combined in
longitudinal studies. The adoption and creation of new machine
learning will be critical to this effort.
A remaining challenge is to translate measurements of nephron
endowment number for in vivo imaging in humans.49 A clinical
measure of nephron number or glomerular volume would poten-
tially allow for individualized therapies tailored to observations in
specific patients and could provide an entirely new view of human
renal development.
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